Your browser doesn't support javascript.
loading
Post-acute COVID-19 cognitive impairment and decline uniquely associate with kynurenine pathway activation: a longitudinal observational study
Lucette Adeline Cysique; David Jakabek; Sophia G Bracken; Yasmin Allen-Davidian; Benjamin Heng; Sharron Chow; Mona Dehhaghi; Ananda Staats-Pires; David Ross Darley; Anthony Byrne; Chansavath Phetsouphanh; Anthony Kelleher; Gregory Dore; Gail V Matthews; Gilles Guillemin; Bruce J Brew.
Afiliação
  • Lucette Adeline Cysique; The University of New South Wales, St. Vincent's Hospital Sydney Australia
  • David Jakabek; St. Vincent's Hospital Sydney Australia
  • Sophia G Bracken; The University of New South Wales
  • Yasmin Allen-Davidian; Macquarie University, St. Vincent's Hospital Sydney Australia
  • Benjamin Heng; Macquarie University
  • Sharron Chow; Macquarie University
  • Mona Dehhaghi; Macquarie University
  • Ananda Staats-Pires; Macquarie University
  • David Ross Darley; St. Vincent's Hospital Sydney Australia
  • Anthony Byrne; St. Vincent's Hospital Sydney Australia
  • Chansavath Phetsouphanh; The Kirby Institute, University of New South Wales
  • Anthony Kelleher; The Kirby Institute, University of New South Wales
  • Gregory Dore; The Kirby Institute, University of New South Wales, St. Vincent's Hospital Sydney Australia
  • Gail V Matthews; The Kirby Institute, University of New South Wales, St. Vincent's Hospital Sydney
  • Gilles Guillemin; Macquarie University
  • Bruce J Brew; St. Vincent's Hospital Sydney, The University of New South Wales
Preprint em Inglês | medRxiv | ID: ppmedrxiv-22276020
ABSTRACT
Cognitive impairment and function post-acute mild to moderate COVID-19 are poorly understood. We report findings of 128 prospectively studied SARS-CoV-2 positive patients. Cognition and olfaction were assessed at 2-, 4- and 12-months post-diagnosis. Lung function, physical and mental health were assessed at 2-month post diagnosis. Blood cytokines, neuro-biomarkers, and kynurenine pathway (KP) metabolites were measured at 2-, 4-, 8- and 12- months. Mild to moderate cognitive impairment (demographically corrected) was present in 16%, 23%, and 26%, at 2-, 4- and 12-months post diagnosis, respectively. Overall cognitive performance mildly, but significantly (p<.001) declined. Cognitive impairment was more common in those with anosmia (p=.05), but only at 2 months. KP metabolites quinolinic acid, 3-hydroxyanthranilic acid, and kynurenine were significantly (p<.001) associated with cognitive decline. The KP as a unique biomarker offers a potential therapeutic target for COVID-19-related cognitive impairment.
Licença
cc_by_nc_nd
Texto completo
Adicionar na Minha BVS
Imprimir
XML
Buscar no Google
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Estudo observacional / Estudo prognóstico Idioma: Inglês Ano de publicação: 2022 Tipo de documento: Preprint
Texto completo
Adicionar na Minha BVS
Imprimir
XML
Buscar no Google
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Estudo observacional / Estudo prognóstico Idioma: Inglês Ano de publicação: 2022 Tipo de documento: Preprint